CHMP's Positive Opinion Opens Doors for Broader Use of Amgen's Repatha® to Reduce First Heart Attack and Stroke Risks

Embracing Change in Cardiovascular Treatment with Repatha®

On July 31, 2026, Amgen Inc. (NASDAQ: AMGN) made headlines with a significant development regarding its innovative cholesterol-lowering medication, Repatha® (evolocumab). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive recommendation to broaden the use of Repatha, particularly for adults suffering from atherosclerotic cardiovascular disease (ASCVD) or those at high risk of developing it. This decision comes as a critical move towards preventing first heart attacks and strokes, addressing a prominent need within the healthcare community.

The recommendation is substantiated by the results of the Landmark Phase 3 Global VESALIUS-Cardiovascular Trial, which involved over 12,000 patients, highlighting the drug's efficacy in significantly reducing the risk of major adverse cardiovascular events (MACE). This development underscores Repatha as the only PCSK9 inhibitor with established proven benefits at this level of clinical research.

In the words of Amgen’s Chief Medical Officer, Dr. Paul Burton, the positive CHMP opinion reflects both the strength of Repatha’s clinical data and the urgent need for effective treatments among patients whose cholesterol levels remain above recommended target ranges despite existing lipid-lowering therapies. This need for effective alternatives is critical; traditional therapies often fall short in achieving desired cholesterol levels, contributing to ongoing cardiovascular risks.

The Importance of PCSK9 Inhibition

Repatha represents a breakthrough in cholesterol management, functioning as a fully human monoclonal antibody that inhibits PCSK9—an enzyme that reduces the number of LDL receptors on the liver, which play a crucial role in clearing LDL cholesterol from the bloodstream. By binding to PCSK9, Repatha allows more LDL receptors to remain available, thus diminishing overall LDL cholesterol levels in patients.

Positive Clinical Outcomes

The VESALIUS-CV study demonstrated that the addition of Repatha to statin-based therapy resulted in a relative risk reduction of 25% in death from ischemic heart disease, heart attacks, or ischemic strokes. Furthermore, the analysis revealed a 36% reduction in the rate of heart attacks specifically among high-risk participants, reinforcing Repatha's position as an invaluable asset in the arsenal against cardiovascular diseases.

This medication was initially approved in the European Union in 2015 and since then has been used by over 10 million patients worldwide. The anticipated swift approval from the European Commission could expand access to this vital therapy for many patients struggling to manage their cardiovascular health effectively.

Addressing Unmet Medical Needs

The ongoing challenge of cardiovascular diseases, which remain the leading cause of mortality globally, necessitates an urgent response from the medical community. Current studies indicate that over 99% of individuals experiencing their first major cardiovascular event carry at least one traditional risk factor, such as elevated LDL cholesterol levels that are often not sufficiently controlled via existing medications.

Amgen's commitment to addressing these unmet needs drives its research and development efforts. It seeks to redefine the landscape of cardiometabolic therapy through a deep understanding of human biology and innovative therapeutic avenues. The positive opinion from CHMP is but one step towards making Repatha available to more patients who could greatly benefit from its protective effects.

Looking Forward

As the EMA’s Committee prepares for final deliberations on the expanded use of Repatha, the potential to redefine treatment paradigms for various high-risk cardiovascular patients is imminent. Should the European Commission grant approval, this will instigate a significant shift in how clinicians approach the management of atherosclerotic cardiovascular conditions.

In a field where the stakes are exceptionally high, Repatha stands out not just as a medication, but as a beacon of hope for patients aiming to achieve better cardiovascular health outcomes. The landscape of treatment is evolving, and the outlook for patients at risk of heart attacks and strokes is steadily improving. This is an exciting time for both Amgen and the countless individuals whose lives may soon be transformed through effective cholesterol management.